| 3.25 -0.24 (-6.88%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.53 | 1-year : | 5.29 |
| Resists | First : | 3.88 | Second : | 4.53 |
| Pivot price | 3.38  |
|||
| Supports | First : | 2.52 | Second : | 1.69 |
| MAs | MA(5) : | 3.44 |
MA(20) : | 3.3 |
| MA(100) : | 2.02 |
MA(250) : | 2.01 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 48.7 |
D(3) : | 61.3 |
| RSI | RSI(14): 58.1 |
|||
| 52-week | High : | 3.88 | Low : | 1.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ABIO ] has closed above bottom band by 28.5%. Bollinger Bands are 27.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.51 - 3.53 | 3.53 - 3.54 |
| Low: | 3.14 - 3.16 | 3.16 - 3.18 |
| Close: | 3.22 - 3.25 | 3.25 - 3.28 |
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Sun, 28 Apr 2024
StockNews.com Begins Coverage on ARCA biopharma (NASDAQ:ABIO) - MarketBeat
Sun, 28 Apr 2024
ARCA biopharma (NASDAQ:ABIO) Now Covered by Analysts at StockNews.com - Defense World
Fri, 26 Apr 2024
Short Interest in ARCA biopharma, Inc. (NASDAQ:ABIO) Rises By 2792.2% - Defense World
Tue, 09 Apr 2024
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc ... - PR Newswire
Thu, 04 Apr 2024
Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth - Simply Wall St
Wed, 03 Apr 2024
Arca Biopharma stock ($ABIO) soars on merger news - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 71.8 (%) |
| Shares Short | 196 (K) |
| Shares Short P.Month | 182 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11.1 % |
| Return on Equity (ttm) | -13.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -8.79 |
| PEG Ratio | 0 |
| Price to Book value | 1.27 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|